TW200628151A - Combinations of therapeutic agents for treating cancer - Google Patents

Combinations of therapeutic agents for treating cancer

Info

Publication number
TW200628151A
TW200628151A TW094144288A TW94144288A TW200628151A TW 200628151 A TW200628151 A TW 200628151A TW 094144288 A TW094144288 A TW 094144288A TW 94144288 A TW94144288 A TW 94144288A TW 200628151 A TW200628151 A TW 200628151A
Authority
TW
Taiwan
Prior art keywords
inhibitor
kinase inhibitor
combinations
therapeutic agents
treating cancer
Prior art date
Application number
TW094144288A
Other languages
English (en)
Inventor
Sara Zaknoen
Margaret Ma Woo
Richard William Versace
Claudio Pisano
Loredana Vesci
Original Assignee
Novartis Ag
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36463409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200628151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Sigma Tau Ind Farmaceuti filed Critical Novartis Ag
Publication of TW200628151A publication Critical patent/TW200628151A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW094144288A 2004-12-15 2005-12-14 Combinations of therapeutic agents for treating cancer TW200628151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63643904P 2004-12-15 2004-12-15

Publications (1)

Publication Number Publication Date
TW200628151A true TW200628151A (en) 2006-08-16

Family

ID=36463409

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144288A TW200628151A (en) 2004-12-15 2005-12-14 Combinations of therapeutic agents for treating cancer

Country Status (26)

Country Link
US (1) US8975248B2 (zh)
EP (1) EP1827437B1 (zh)
JP (1) JP5345323B2 (zh)
KR (1) KR101367516B1 (zh)
CN (1) CN101080227B (zh)
AT (1) ATE531371T1 (zh)
AU (1) AU2005316652B2 (zh)
BR (1) BRPI0515774A (zh)
CA (1) CA2589521C (zh)
CY (1) CY1112368T1 (zh)
DK (1) DK1827437T3 (zh)
ES (1) ES2374828T3 (zh)
HR (1) HRP20110960T1 (zh)
IL (1) IL183595A0 (zh)
MA (1) MA29096B1 (zh)
MX (1) MX2007007212A (zh)
NO (1) NO20073552L (zh)
NZ (1) NZ555370A (zh)
PL (1) PL1827437T3 (zh)
PT (1) PT1827437E (zh)
RU (1) RU2400232C2 (zh)
SI (1) SI1827437T1 (zh)
TN (1) TNSN07224A1 (zh)
TW (1) TW200628151A (zh)
WO (1) WO2006065780A2 (zh)
ZA (1) ZA200704701B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767664C2 (ru) * 2010-11-12 2022-03-18 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332811A1 (en) 2002-09-06 2018-06-13 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering covalently attached camptothecin
JP5345323B2 (ja) 2004-12-15 2013-11-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 癌を処置するための治療剤の組合せ
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
WO2007094026A1 (en) * 2006-02-17 2007-08-23 Paolo La Colla Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
EP2606890A1 (en) * 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CA2645242A1 (en) * 2006-04-05 2007-10-11 Novartis Ag Combinations of therapeutic agents for treating cancer
BRPI0709750A2 (pt) * 2006-04-05 2011-07-26 Novartis Ag combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
NZ725303A (en) * 2014-04-04 2019-02-22 Taiho Pharmaceutical Co Ltd Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016201481A1 (en) 2015-06-15 2016-12-22 Newsouth Innovations Pty Limited Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors
CN107951888A (zh) * 2017-12-19 2018-04-24 天津科技大学 阿法替尼与10-羟基喜树碱的药物组合及其应用
CN109091480A (zh) * 2018-09-19 2018-12-28 天津科技大学 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途
JPWO2020130125A1 (ja) * 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN111789903A (zh) * 2019-04-08 2020-10-20 石小和 治疗尿道癌的药物组合物及其制备方法
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531722T2 (de) 1994-11-11 2004-07-01 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
US7105492B2 (en) 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003037897A2 (en) 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
MXPA05000485A (es) * 2002-07-11 2005-04-19 Combinatorx Inc Combinacion de farmacos para el tratamiento de neoplasmas.
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1761281A1 (en) * 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
JP5345323B2 (ja) 2004-12-15 2013-11-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 癌を処置するための治療剤の組合せ
JP4702322B2 (ja) 2006-12-14 2011-06-15 トヨタ自動車株式会社 内燃機関の制御装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767664C2 (ru) * 2010-11-12 2022-03-18 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом

Also Published As

Publication number Publication date
RU2400232C2 (ru) 2010-09-27
RU2007126978A (ru) 2009-01-27
AU2005316652B2 (en) 2009-07-23
EP1827437A2 (en) 2007-09-05
BRPI0515774A (pt) 2008-08-05
CA2589521C (en) 2014-04-01
MX2007007212A (es) 2007-11-07
WO2006065780A2 (en) 2006-06-22
SI1827437T1 (sl) 2012-02-29
ZA200704701B (en) 2008-09-25
PL1827437T3 (pl) 2013-06-28
CN101080227B (zh) 2011-08-31
ATE531371T1 (de) 2011-11-15
IL183595A0 (en) 2007-10-31
NZ555370A (en) 2010-03-26
KR20070091286A (ko) 2007-09-10
WO2006065780A3 (en) 2006-08-17
MA29096B1 (fr) 2007-12-03
ES2374828T3 (es) 2012-02-22
HRP20110960T1 (hr) 2012-01-31
PT1827437E (pt) 2012-01-12
CA2589521A1 (en) 2006-06-22
JP2008524225A (ja) 2008-07-10
CY1112368T1 (el) 2015-12-09
DK1827437T3 (da) 2012-02-13
EP1827437B1 (en) 2011-11-02
AU2005316652A1 (en) 2006-06-22
CN101080227A (zh) 2007-11-28
KR101367516B1 (ko) 2014-02-27
JP5345323B2 (ja) 2013-11-20
US20100028338A1 (en) 2010-02-04
NO20073552L (no) 2007-09-12
TNSN07224A1 (en) 2008-11-21
US8975248B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
TW200628151A (en) Combinations of therapeutic agents for treating cancer
WO2005027972A3 (en) Combination of a vegf receptor inhibitor with a chemotherapeutic agent
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
Ferrario et al. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
WO2004037341A3 (en) Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
Wei et al. Effect of captopril on radiation-induced TGF-β1 secretion in EA. Hy926 human umbilical vein endothelial cells
AU2003244762A1 (en) Methods and compositions for intravesical therapy of bladder cancer
JP5749170B2 (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
JP2008516921A (ja) 多剤耐性の治療および予防
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
TW200503798A (en) Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy
DK1687642T3 (da) Screeningsfremgangsmåder til kombinationer af biologiske forbindelser
EA202092513A1 (ru) Комбинированная терапия
RU2005110536A (ru) Способ лечения рака